CCL8 expression in human serum after HSCT. Serum was obtained at several time points after HSCT. The results of immunoSELDI using antibody specific for human CCL8 are shown. Box highlights peak of human CCL8. The predicted molecular mass of mature human CCL8 is 8920 Da. (A) Patient A developed clinical GVHD on day 13 after HSCT and methyl prednisolone (mPSL) was administered the same day. The peak profile of CCL8 was very weak on day 0 with an obvious increase on day 10. CCL8 then declined on day 21 after mPSL treatment, but was again up-regulated on day 33. The peak intensity of 8920 Da was 9.6, 40.6, 19.5, and 52.5 on days 0, 10, 21, and 33, respectively. (B) In patient B, no CCL8 peak was detected on day 0, but was increased on days 9 and 19, and decreased on days 21 and 30. Clinical GVHD was overt on day 19 and mPSL treatment was started. The peak intensity of 8920 Da is 2.1, 14.3, 41.4, 12.3, and 12.7 on days 0, 9, 19, 21, and 30, respectively. (C) No GVHD developed in patient C throughout the course. CCL8 peak was very low in all samples examined. The peak intensity of 8920 Da is 5.8, 12.8, 4.1, 6.5, 6.2, and 3.0 on days −7, −1, 10, 20, 34, and 38, respectively. (D) An example of CCL8 expression in a healthy control is shown. CCL8 peak is very low. The peak intensity of 8920 Da is 5.3.